1. Gurgel JA, Lima-Júnior RC, Rabelo CO, Pessoa BB, Brito GA, Ribeiro RA. Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation. Rev Bras Psiquiatr 2013; 35:387-392.
2. Bohren Y, Tessier LH, Megat S, Petitjean H, Hugel S, Daniel D, et al. Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism. Neurobiol Dis 2013; 60:39-50
3. Panahi Y, Davoudi SM, Beiraghdar F, Amiri M. Doxepin cream vs betamethasone cream for treatment of chronic skin lesions due to sulfur mustard. Skin Med 2011; 9:152-158.
4. Kostadinov ID, Delev DP, Murdjeva MA, Kostadinova II. Experimental study on the role of 5-HT2 serotonin receptors in the mechanism of anti-inflammatory and antihyperalgesic action of antidepressant fluoxetine. Folia Med (Plovdiv) 2014; 56:43-49.
5. Saito H, Wakai J, Sekiguchi M, Kikuchi S, Konno S. The effect of selective serotonin reuptake inhibitor (SSRI) on pain-related behavior in a rat model of neuropathic pain. Eur Spine J 2014; 23:2401-249.
6. Hochstrasser T, Ehrlich D, Sperner-Unterweger B, Humpel C. Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets. Pharmacopsychiatry 2013; 6:29-34.
7. Baldessarini R J. Drugs for the treatment of psychiatric disorders. In: Hardman JG, LE. Limbird LE. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th eds. McGraw Hill, New York: USA: 2001.p.447–483.
8. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001; 35:557–559.
9. Cegielska-Perun K, Bujalska-Zadrożny M, Tatarkiewicz J, Gąsińska E, Elżbieta H, Nowak M. Venlafaxine and neuropathic pain. Pharmacology 2013; 91:69–76.
10. Dwight MM, Arnold LM, O’Brien H, Metzger R, Morris-Park E, Keck PE. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998; 39:14–17.
11. Ellingrod VL, Perry PJ.Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51:3000-3046.
12. Budantsev AI, Kisliuk OS, Shul'govskii VV, Rykunov DS, Iarkov AV. The brain in stereotaxic coordinates (a textbook for colleges). Zh Vyssh Nerv Deiat Im 1993; 43:1045–1051.
13. Winter CA, Risely EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 1962; 111:544–547.
14. Aricioğlu F, Buldanlioğlu U, Salanturoğlu G, Ozyalçin NS. Evaluation of antinociceptive and anti-inflammatoryeffects of venlafaxine in the rat. Agri 2005; 17:41-46.
15. Hajhashemi V, Banafshe HR, Minaiyan M, Mesdaghinia A, Abed A. Antinociceptive effects of venlafaxine in a rat model of peripheral neuropathy: role of alpha2-adrenergic receptors. Eur J Pharmacol 2014 5; 738:230-236
16. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement ofcutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78:206–209.
17. Sadeghi H, Hajhashemi V, Minaiyan M, Movahedian A, Talebi A. A study on the mechanismsinvolving the anti-inflammatoryeffect of amitriptyline in carrageenan-inducedpawedema in rats. Eur J Pharmacol 2011; 667:396-401.
18. Gilligan JP, Lovato SJ, Erion MD, Jeng AY. Modulation of carrageenan induced hind paw edema by substance P. Inflammation 1994; 18:285–292.
19. Halici Z, Dengiz GO, Odabasoglu F, Suleyman H, Cadirci E, Halici M. Amiodarone has anti-inflammatory and anti-oxidative properties: an experimental study in rats with carrageenan-induced paw edema. Eur J Pharmacol 2007; 566:215–221.
20. Nacife VP, Soeiro MN, Gomes RN, D'Avila H, Castro-FariaNeto HC, Meirelles MN. Morphological and biochemical characterization of macrophages activated by carrageenan and lipopolysaccharide in vivo. Cell Struct Funct 2004; 29:27–34.
21. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 2010; 23:205–211.
22. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223:7–19.
23. Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004; 3:263–269.
24. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51:289–298.
25. Kovaru H, Pav M, Kovaru F, Raboch J, Fiserova A. Cell signaling in CNS and immune system in depression and during antidepressant treatment: focus on glial and natural killer cells. Neuro Endocrinol Lett 2009; 30:421–428.
26. Tian L, Rauvala H, Gahmberg CG. Neuronal regulation of immune responses in the central nervous system. Trends Immunol 2009; 30:91–99.
27. Eskandari F, Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther 2003; 5:251–265.
28. Berrocoso E, Mico JA. In vivo effect of venlafaxine on locus coeruleus neurons: role of opioid, α2-Adrenergic, and 5-Hydroxytryptamine1A receptors. J Pharmacol Exp Ther 2007; 322:101-107.
29. Egan TM, Henderson G, North RA, Williams JT. Noradrenaline-mediated synaptic inhibition in rat locus coeruleusneurones. J Physiol 1983; 345:477–488.
30. Iravani MM, Sadeghian M, Rose S, Jenner P. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. J Neural Transm 2014; 121:1493-1505.
31. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979; 310:175–183.